Komori
Share Issuance and Disposal4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Regarding the Monthly Exercise Status of the 58th and 66th Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Provisions)

In June 2026, 550 Series 66 stock acquisition rights were exercised, and 55,000 new shares were issued. No Series 58 stock acquisition rights were exercised.

Worth reading
58In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
55000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status of stock acquisition rights with an exercise price adjustment clause issued through third-party allotment

発行・処分する株式数

Series 66 stock acquisition rights 55,000 shares (new shares) / Series 58 stock acquisition rights 0 shares

発行済株式総数

0.1% (the exercise ratio under the exercise limit; the 55,000 shares delivered during the relevant month represented approximately 0.07% of the 76,361,760 issued shares at the end of the preceding month)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
¥84. Although the warrants have an exercise price adjustment clause, the adjustment floor was not disclosed
Number of Stock Acquisition Rights
Total number issued Series 66: 200,000 rights; Series 58: 20,000 rights / Unexercised balance As of the end of the relevant month: Series 66: 158,450 rights; Series 58: 20,000 rights
Most recent equity financing
Timing 1 June 2022 / Type Issuance of Series 58 stock acquisition rights / Amount Not disclosed, Timing 12 August 2025 / Type Issuance of Series 66 stock acquisition rights / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status of stock acquisition rights with an exercise price adjustment clause issued through third-party allotment
Number of shares to be issued or disposed ofSeries 66 stock acquisition rights 55,000 shares (new shares) / Series 58 stock acquisition rights 0 shares
Dilution Rate0.1% (the exercise ratio under the exercise limit; the 55,000 shares delivered during the relevant month represented approximately 0.07% of the 76,361,760 issued shares at the end of the preceding month)
Total number of issued shares76,361,760 shares (as of the end of the month preceding the relevant month) → Not disclosed
Exercise price¥84. Although the warrants have an exercise price adjustment clause, the adjustment floor was not disclosed
Number of Stock Acquisition RightsTotal number issued Series 66: 200,000 rights; Series 58: 20,000 rights / Unexercised balance As of the end of the relevant month: Series 66: 158,450 rights; Series 58: 20,000 rights
Most recent equity financingTiming 1 June 2022 / Type Issuance of Series 58 stock acquisition rights / Amount Not disclosed, Timing 12 August 2025 / Type Issuance of Series 66 stock acquisition rights / Amount Not disclosed
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This is a report on the monthly exercise status; no reason for the exercises is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 58th and 66th Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Provisions) | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori